SCTX

Scribe Therapeutics Inc.

Healthcare · Biotechnology

16.20$ -3.5% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Income Statement

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement SCTX
Line item	Q1 25	Q2 25	Q1 26	Q2 26
Revenue	100.0%	100.0%	100.0%	100.0%
Research & Development	93.4%	283.5%	506.3%	460.0%
Selling, General & Administrative	39.1%	53.9%	150.2%	129.8%
Total Operating Expenses	132.4%	337.4%	656.5%	589.8%
Operating Income	-32.4%	-237.4%	-556.5%	-489.8%
Interest Expense	3.5%	12.2%	26.8%	14.4%
Pre-Tax Income	-21.8%	-216.7%	-766.6%	-326.6%
Net Income	-20.0%	-202.2%	-776.8%	-337.7%
EBITDA	-13.3%	-187.4%	-705.2%	-271.3%

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.